Today’s Research Reports on Stocks to Watch: Pulmatrix and Aevi Genomic Medicine

NEW YORK, NY / ACCESSWIRE / March 22, 2017 / The choice of technology a biotech company pursues can be critical to stock success and investor decision making. It is a general rule that the biotech sector is risky in part because it is a “winner take all” attitude for an individual company. Promise and potential do not always end up resulting in profit, and these two stocks are evidence of that logic.

RDI Initiates Coverage:

Pulmatrix Inc.

https://ub.rdinvesting.com/news/?ticker=PULM

Aevi Genomic
Medicine, Inc

https://ub.rdinvesting.com/news/?ticker=GNMX

Pulmatrix saw its stock rise almost 40 percent on Tuesday, to close at $3.88 a share. The $1.10 increase was due to the company’s announcement of being awarded a European patent on its iSPERSE inhaled drug technology. The company continues its research and development on several other therapies, including treatments for COPD and fungal infections. The specific European patent, EP 2410981 B1, is yet another intellectual property victory for the company, as it already has similar established patents in the United States and Japan. The iSPERSE delivery system is unique in delivery mechanisms of drugs to the lungs, as it allows a greater amount of the medication to reach the lungs, thereby minimizing side effects of drug that stuck into throat or mouth, caused by other delivery systems. With proceed of nearly $7.5 million along with the cash and cash equivalents of $4.2 million reported at the end of December 2016, the company has relatively healthy balance sheet as compared to the last quarter, but the possible requirement of more cash present range of opportunities as well as risks to the investors.

Access RDI’s Pulmatrix Research Report at: https://ub.rdinvesting.com/news/?ticker=PULM

Aevi Genomic stock fell from its opening high of $2.25 a share to close at $1.75 on Tuesday. The company has reported the top-line results on its ADHD drug, AEVI-001, with mixed news. The primary goal of the Phase 2 trial was to meet the endpoint – the efficacy of the drug on adolescent patients as measured by the ADHD rating scale, which it didn’t met. However, there was a positive result on a secondary measurement, inattentiveness. Another important event was the drug had an excellent tolerance in high doses used by the patients, and no significant side effects were noted. The stock’s price has dropped almost 70 percent since the report was released on 20th March, and while the company has nearly $40 million in cash sufficient enough to continue its current operations till the end of first quarter 2018, but to continue to pursue successfully completing the FDA trials and bring the drug to market will likely require more cash. If the company decides to issue additional stock, the price for existing shareholders is certain to be diluted.

Access RDI’s Aevi Genomic Research Report at: https://ub.rdinvesting.com/news/?ticker=GNMX

Our Actionable Research on Pulmatrix Inc. (NASDAQ: PULM) and Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457916